U1. Protein Production Platform (PPP)
- Strategy Director: Prof. Antonio Villaverde email@example.com
- Scientific Director: Dr. Neus Ferrer Miralles firstname.lastname@example.org
- Technical Coordinator: Dr. Paolo Saccardo email@example.com
- General email: firstname.lastname@example.org
- Entities: Institute of Biotechnology and Biomedicine (IBB) & Autonomous University of Barcelona (UAB)
- Address: Campus Bellaterra, 08193 Bellaterra, Barcelona, Spain
- Phone: +34 935 812 864
- Web: UAB – IBB
The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.
Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.
The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.
- U1-S01. Molecular cloning (On-site&Remote) OUTSTANDING
- U1-S02. Bioproduction of proteins (On-site&Remote) OUTSTANDING
- U1-S03. Proteins purification (On-site&Remote) OUTSTANDING
- U1-S04: Consultancy in protein production (On-site&Remote)
- U1-S05: Training courses in protein production (On-site&Remote)
- U1-S06: Criopreservation (On-site&Remote)
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
Unit 1 of NANBIOSIS, together with Synchroton Alba and the pharmaceutical ESTEVE jointly investigate the mechanisms of new inhibitors against pain ESTEVE, a chemical – pharmaceutical group leader in Spain and with an important international presence, has developed new inhibitors against pain. Collaboration with scientific expertise of the Protein Production Platform and the ALBA Synchrotron will allow studyingthe interaction of these inhibitors with its potential target. The results of the research may help to the better understanding of the effects of the inhibitors and will provide key information to improve their properties. The Protein Production Platform (Unit 1 of NANBIOSIS) is in[...]
“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”
Unit 1 of NANBIOSIS, Protein Production Platform (PPP), Unit 3, Synthesis of Peptides, Unit 20, In Vivo Experimental Platform and Unit 6, Biomaterial Processing and Nanostructuring Unit, have jointly developed the research conducted in relation with a CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bio-active nanomaterials with therapeutic interest. The results have been published in Advanced Healthcare Materials: http://www.ncbi.nlm.nih.gov/pubmed/26890358 “a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo, P. Rivera, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D. Pulido,[...]
Unit 1 of NANBIOSIS, Production Platform Protein (PPP) at the Autonomous University of Barcelona, directed by Dra. Neus Ferrer and coordinated by Professor Antonio Villaverde, provides the service of production and purification of recombinant proteins in different systems expression, microbial and non-microbial. This service was audited last November, based on the UNE EN ISO 9001: 2008 AENOR, who has issued a favourable certification report. The requirements of this standard cover all aspects of management. This certification will expand and consolidate the service that the Unit 1 of NANBIOSIS is giving to companies and public sector researchers and facilitate their integration[...]
Researchers from the Folding and Conformational Diseases Group at the Institute of Biotechnology and Biomedicine Group are part of the European project Neuromed to develop molecules and detect biomarkers of this disease before the signs of neurodegeneration become evident. The Neuromed project is led by the University of Zaragoza and aims to design molecules, drugs and new diagnostic tools early for three neurodegenerative diseases in which defective proteins are involved: Parkinson’s disease and two rare diseases, phenylketonuria and protein TTR Amyloidosis. The coordination of the Parkinson’s research line will be directed, from the IBB, by Salvador Ventura, principal researcher and[...]